C07K 14/1816
Flaviviridae
Official title: {Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus}
C07K14/1816 (Flaviviridae) appears on 93 US grants and 128 published applications in this corpus.
Search patents in C07K- Granted patents
- 93
- Published applications
- 128
- Assignees
- 86
- Inventors
- 201
- Latest grant
- 14 Apr 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2004 | 0 | 1 |
| 2005 | 0 | 1 |
| 2006 | 0 | 1 |
| 2007 | 0 | 0 |
| 2008 | 1 | 1 |
| 2009 | 1 | 1 |
| 2010 | 0 | 1 |
| 2011 | 0 | 0 |
| 2012 | 2 | 1 |
| 2013 | 1 | 9 |
| 2014 | 5 | 2 |
| 2015 | 4 | 1 |
| 2016 | 1 | 1 |
| 2017 | 1 | 3 |
| 2018 | 4 | 18 |
| 2019 | 8 | 20 |
| 2020 | 11 | 18 |
| 2021 | 10 | 10 |
| 2022 | 16 | 10 |
| 2023 | 7 | 11 |
| 2024 | 11 | 6 |
| 2025 | 8 | 5 |
| 2026 | 2 | 7 |
By publication year. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Methods and compositions for recombinant dengue viruses or vaccine and diagnostic development14 Apr 2026US 12,600,752 B2The University of North Carolina at Chapel Hill
- Highly specific zika neutralizing human antibodies27 Jan 2026US 12,534,517 B2The University of North Carolina at Chapel Hill
- Vaccines against Zika virus23 Sep 2025US 12,419,945 B2The Trustees of the University of Pennsylvania
- Anti-dengue vaccines and antibodies16 Sep 2025US 12,415,836 B2Oxford University Innovation Limited
- Methods and compositions for treating yellow fever2 Sep 2025US 12,404,319 B2Wuxi Biologics Ireland Limited
- Dengue virus serotype-specific modulation of t cell responses8 Oct 2026US 2026/0306621 A1The United States Government as represented by the Department of Veterans Affairs
- Engineered flavivirus envelope glycoprotein immunogenic compositions and methods of use2 Jul 2026US 2026/0184744 A1University of Maryland, Baltimore
- Zika and hcv attenuated viruses and use thereof2 Jul 2026US 2026/0185060 A1Bar-Ilan University
- Polynucleotides and lentiviral vectors expressing non-structural antigens of a flavivirus selected from the group of denv, zikv and yfv, inducing protective cd8+ t-cell immunity in a host9 Apr 2026US 2026/0097108 A1
- Zikv-based gene delivery system19 Mar 2026US 2026/0078403 A1The Regents of the University of California
Most cited
By later US patents
- High potency immunogenic zika virus compositions92US 10,273,269 B2ModernaTX, Inc. · 2019
- Zika RNA vaccines85US 10,449,244 B2ModernaTX, Inc. · 2019
- Virus purification14US 10,537,630 B2Valneva SE · 2020
- Dengue and West Nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications13US 7,556,812 B2Centre National De La Recherche Scientifique · 2009
- Compositions and methods that enhance an immune response11US 8,445,663 B2Chrontech Pharma AB · 2013